Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-12-04
2003-12-16
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S432000, C514S460000, C514S210200, C514S252140, C514S252180, C514S256000, C514S253030, C514S151000, C514S304000, C514S332000, C514S333000, C514S318000, C544S295000, C544S296000, C546S216000, C549S028000, C549S416000, C552S001000, C568S327000
Reexamination Certificate
active
06664272
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to compounds useful for the treatment of cancer, and in particular to compounds exhibiting anti-tumor and anti-angiogenic properties and methods for using such compounds.
BACKGROUND OF THE INVENTION
Tissue factor (TF) is a sedimentable, integral membrane receptor protein with an estimated molecular weight of 42-47 kDa. Peritumor fibrin deposition, which is characteristic of most types of human cancer, is the result of the local expression of potent procoagulants like tissue factor (TF) in tumor cells, tumor-associated macrophages (TAMs) and tumor-associated vascular endothelial cells (VECs). In addition to the importance of TF expression in the pathogenesis of the thrombotic complications common to cancer patients, increasing evidence links TF expression to the regulation of tumor angiogenesis, growth and metastasis. For example, angiogenesis in vivo is inhibited by TF antisense. Further, murine tumor cells transfected to overexpress TF enhance vascular permeability factor (VEGF) transcription and translation. Conversely, tumor cells transfected with TF antisense reduce VEGF transcription and translation. VEGF acts specifically on VECs to promote vascular permeability, endothelial cell growth and angiogenesis, and has been shown to induce expression of TF activity in VECs and monocytes and is chemotactic for monocytes, osteoblasts and VECs. Expression of TF and VEGF in cancer cells is further enhanced under hypoxic condition. Thus, there is evidence to suggest that TF is a key molecule participating in the regulation of VEGF synthesis and, hence, tumor angiogenesis in cancer.
Relatively few compounds exhibiting anti-angiogenic properties useful in the treatment of cancer have been investigated. Curcumin (diferuloylmethane), the aromatic yellow pigment in curry, turmeric and mustard, is known to have anti-angiogenic, anti-tumor, and anti-tumor promoting properties. In addition, curcumin exhibits numerous other therapeutic effects, including anti-oxidative, anti-thrombotic, anti-inflammatory, anti-cholesterol and anti-diabetic properties. Two other compounds that have received considerable attention are genistein, a soybean-derived isoflavone tyrosine kinase C inhibitor, and linomide, a quinoline-3-carboxaminde. Certain flavonoids, such as apigenin, have been shown to be more potent inhibitors of cell proliferation and in vitro angiogenesis than genistein. There remains a need in the art for compounds that exhibit anti-tumor and anti-angiogenic properties for use in cancer therapy.
SUMMARY OF THE INVENTION
The present invention provides a group of curcumin analogs that inhibit TF expression and VEGF expression in cancer cells and in vascular endothelial cells in the tumor microenvironment, thereby blocking tumor angiogenesis and growth, without exhibiting a high level of toxicity with regard to normal vascular endothelial cells. The anti-angiogenic and anti-tumor compounds of the present invention can be useful in the treatment of any condition benefiting from angiogenesis inhibition, such as cancer.
In one aspect, the present invention provides compounds of Formula (I) below.
In another aspect, the present invention provides a pharmaceutical formulation comprising a compound of Formula (I) or Formula (II) below in a pharmaceutically acceptable carrier.
In a third aspect, the present invention provides a method of treating cancerous tissue in a subject, comprising administering an effective amount of a compound of Formula (I) or Formula (II) to the subject. Preferably, the compound is administered in a pharmaceutically acceptable carrier. The effective amount is preferably an amount sufficient to inhibit VEGF or TF production in the cancerous tissue.
REFERENCES:
patent: 3114775 (1963-12-01), Hughes et al.
patent: 3911129 (1975-10-01), Krapcho et al.
patent: 4127667 (1978-11-01), Rovnyak
patent: 4415621 (1983-11-01), Specht et al.
patent: 4755450 (1988-07-01), Sanders et al.
patent: 4987057 (1991-01-01), Kaji et al.
patent: 5700804 (1997-12-01), Collins et al.
patent: 5811218 (1998-09-01), Kaji et al.
patent: 5852018 (1998-12-01), Bryans et al.
patent: 6022597 (2000-02-01), Yan et al.
patent: 2002/0006966 (2002-01-01), Arbiser
patent: 03 44643 (1991-02-01), None
patent: WO 01/46110 (2001-06-01), None
Zheng et al Zhongguo Yiyao Gonye Zazhi, 28(5), 230231, 1997, CA 115: 102878, 1991.*
Gutkowska et al., Acta Poloniae Pharmaceutica, 46(3): 212-18, 1989, CA112: 216649, 1990.*
Gutkowska et al., Acta Poloniae Pharmaceutica, 42(5): 437-41, 1985, CA 107: 115819, 1987.*
Ojima et al., Bull. Chem. Soc. Jpn, 50(6), 1522-1526, 1977. CA 87: 20055, 1977.*
Shoppee et al., J. Chem. Soc. Perkin Trans. I 9, 1028-1030, 1977. CA 87: 102029, 1977.*
Fujisaki et al. JP 62225562. CA: 108: 77360, 1988.*
Keinan et al., J. Org. Chem. 48(26), 5302-9, 1983.*
Pivnenko et al., Zh. Org. Khim. 11(12), 2527-2533, 1975. CA 84:73234, 1976.*
Pivnenko et al., Zh. Obshch. Khim. 42(5), 1096-1102, 1972. CA 72: 513251, 1972.*
Cremlyn et al., “The Synthesis and Chlorosulfonation of Some Diarylidene and Heteroarylidene Ketones with Varying Alicyclic Ring Size”,Phosphorus, Sulfur, and Silicon, 1995, pp. 205-217, vol. 107.
Hammam et al., “Synthesis and Anti-Cancer Activity of Pyridine and Thiazolopyrimidine Derivatives Using 1-Ethylpiperidone as a Synthon”,Indian J. of Chem., 2001, pp. 213-221, vol. 40B.
Li et al., “Samarium (III) Iodide Promoted Preparation of &agr;,&agr;′—bis(substituted benzylidene) cyclohexanones from benzaldehydes and cyclohexanone”,J. Chem. Research(S), 2000, pp. 580-581.
Mahfouz et al., “Synthese mehrfach oxigenierter 2-Hydroxyxanthone”,Arch. Pharm.(Weinheim), 1990, pp. 163-169, vol. 323.
Nakano et al., “A Convenient Synthesis of &agr;,&agr;′—Bis(substitutedbenzylidene)cycloalkanones”,Chemistry Letters, 1993, pp. 2157-2158.
Wiemer et al., “Vidalols A and B, new anti-inflammatory bromophenols from the Caribbean marine red algaVidalia obtusaloba”,Experientia, 1991, pp. 851-853, vol. 47.
Artico, et al., “Genometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling”,J. Med. Chem., 1998, pp. 3948-3960, vol. 41, No. 21.
Dinkova-Kostova, et al., “Chemoprotective Properties of Phenylpropenoids, Bis(benzylidene)cycloalkanones, and Related Michael Reaction Acceptors: Correlation of Potencies as Phase 2 Enzyme Inducers and Radical Scavengers”,J. Med. Chem., 1998, pp. 5287-5296, vol. 41, No. 26.
El-Subbagh, et al., “Synthesis and Biological Evaluation of Certain &agr;,&bgr;-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents”,J. Med. Chem., 2000, pp. 2915-2921, vol. 43, No. 15.
Sun, et al., “Design, Synthesis, and Evaluations of Substituted 3-[3-or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases”,J. Med. Chem., 1999, pp. 5120-5130, vol. 42, No. 25.
Sun, et al., “Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEFG-R2 (Flk-1/KDR), FGF-R1, and PDGF-R&bgr;Tyrosine Kinases”,J. Med. Chem., 2000, pp. 2655-2663, vol. 43, No. 14.
Sun, et al., “Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases”,J. Med. Chem., 1998, pp. 2588-2603, vol. 41, No. 14.
Teuscher, “Potentiell antiangiogene Substanzen aus der Gruppe der &agr;, &agr;′-Bis(amidinobenzyl)cycloalkanon-Derivate and &agr;-(Arylsulfonylamino)-&ohgr;-phenylcarbonsäure-4-amidinoanilide”,Pharmazie, 1987, pp. 109-110, vol. 42, H.2.
Thaloor, et al., “Inhibition of Angiogenic Differentiation of Human Umbilical Vein Endothelial Cells by Curcumin”,Cell Growth&Differentiation, 1998, pp. 305-312, vol. 9.
Vieth, et al., “DoMCoSAR: A Novel Approach for Establishing the Docking Mode That Is Consistent with the Structure-Activity Relationship. Application to HIV-1 Protease I
Adams Brian
Davis Matthew C.
Ferstl Eva M.
Liotta Dennis C.
Shoji Mamoru
Alston & Bird LLP
Emory University
LandOfFree
Curcumin analogs with anti-tumor and anti-angiogenic properties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Curcumin analogs with anti-tumor and anti-angiogenic properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Curcumin analogs with anti-tumor and anti-angiogenic properties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3136727